Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC43F, a Fixed-dose Combination (FDC) Oral Tablet Containing ASC41, a THR β Agonist and ASC42, an FXR Agonist in Healthy Subjects
Conditions
Interventions
ASC43F
Locations
1
United States
8307 Gault Lane
San Antonio, Texas, United States
Start Date
November 1, 2021
Primary Completion Date
December 7, 2021
Completion Date
December 7, 2021
Last Updated
September 27, 2024
NCT00090662
NCT07310264
NCT06342713
NCT06223555
NCT07472361
NCT01266577
Lead Sponsor
Gannex Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions